Latin America Cancer Metabolism Based Therapeutics Market

The size of the Latin American Cancer Metabolism Based Therapeutics Market is forecasted to hike at a steady CAGR during the forecast period.

The hike in this market is driven by several factors, some of them include an increase in the number of people who are diagnosed with cancer every year, smoking tobacco, exposing the body to different types of radiation, heredity, chemicals. Introducing new ways of treating cancers also increasing the market share. The high cost of treatment may drag back the market value in some of the developing countries. Around 3% of the cancer cases and 7% of cancer-related deaths in the U.S. are attributed to pancreatic cancer.

The market is segmented by Therapy, Drug type, and Indication. By therapy, the market is categorized into Biological drug therapies and Targeted drug therapies. By drug type, the market is further divided into CPI-613, Enasidenib, others. CPI-613 was introduced recently in 2018 which is considered as the best drug to treat pancreatic cancer. Enasidenib also got its importance in treating pancreatic cancer. According to a report from American Cancer Society in 2018, 53 thousand people were diagnosed with pancreatic cancer and around 43 thousand of them are experiencing a threat to their lives. By Indication, the market is segregated into Melanoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Metastatic Renal Cell Carcinoma, and others. Around twenty one thousand cases of Acute Myeloid Leukemia attacks were reported by American Cancer Society in 2018, out of which 50% are experiencing the terminal stage. Many non-profit organizations came into the picture to help people and increased awareness about symptoms and treatment process of pancreatic cancer which is helping the market to increase its size.

By geography, the market is segmented into Brazil, Argentina, Chile, and others. The Latin America Cancer Metabolism Based Therapeutics Market is also showing   optimistic signs of market expansion owing to growing healthcare access and increasing incidence of cancer in these regions.

Some of the prime manufacturers of Cancer Metabolism Based Therapeutics are AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health.